Morag ParkMorag Park CQ FRSC is a breast cancer and genomics researcher at the McGill University Health Centre.[1] Park is known for her work on the combination of genetic and epigenetic alterations that result in breast cancer progression and receptor tyrosine kinases involved in cancer.[2] More recently, she has worked in as primary co-researcher of a Quebec cancer biobank network that creates tumor models derived from patients, allowing for research into why individual patients respond well or poorly to cancer therapies.[3] She is currently a professor in the Gerald Bronfman Department of Oncology and a member of the Faculty of Medicine and Health Sciences at McGill University.[1] EducationPark conducted her undergraduate studies at University of Glasgow and received a B.Sc. with first class honors. She received a PhD in viral carcinogenesis at the Medical Research Council Virology Institute in Scotland and conducted her post-doctoral research at the National Institutes for Cancer Research in Washington, DC.[4] Awards and honors2022 Woman of Distinction Award in Research and Innovation[3][5] Club de Recherches Cliniques du Québec Michel Sarrazin Award (2021)[6] Quebec Breast Cancer Foundation Grand Prix Scientifique (2019)[5] Canadian Cancer Society 2017 Robert L. Noble Prize[7] 2015 Canadian Cancer Research Alliance Award for Exceptional Leadership in Cancer Research[8] References
|